<?xml version="1.0" encoding="UTF-8"?>
<p>DPP-IV inhibitors are used in the treatment of T2DM based on their ability to extend postprandial levels of circulating plasma GLP-1 and GIP, thereby improving insulin secretion and helping to maintain good blood glucose control. Since their introduction to the clinic [
 <xref rid="B15" ref-type="bibr">15</xref>], this drug class has proven to be effective and highly popular. Weight reduction and glycaemic control are inferior to the related family of GLP-1 mimetics but DPP-IV inhibitors have the advantage of being orally active, thereby avoiding the need for daily injections and increasing patient compliance. In certain developing countries, the limited availability and cost of these and other modern medicines, such as metformin, sulphonylureas, thiazolidenediones, SGLT2 inhibitors and insulin formulations, have resulted in increasing attention being paid to traditional plant medicines with reputed anti-diabetic activity for treatment of T2DM [
 <xref rid="B3" ref-type="bibr">3</xref>,
 <xref rid="B8" ref-type="bibr">8</xref>,
 <xref rid="B10" ref-type="bibr">10</xref>,
 <xref rid="B16" ref-type="bibr">16â€“18</xref>].
</p>
